Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
August 19th, 2009
nospam@example.com (Clear the Smoke) wrote an intriguing post today on
Here’s a little taster
Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non–small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment.
Read the rest of this post here
Posted in